#1CYTEK TRANSCEND THE CONVENTIONAL Cytek to Expand Flow Cytometry Portfolio with Amnis and Guava Lines from Luminex February 13, 2023#2Cytek to Acquire Amnis & Guava Lines from Luminex Safe Harbor Statement This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding Cytek's acquisition of the flow cytometry and imaging (FCI) business unit of Luminex, the timing of the closing of the transaction, the expected benefits of the transaction, the integration of the FCI business and employees into Cytek, Cytek's future solutions offerings and product strategy; Cytek's operational and shareholder goals; Cytek's anticipated sales opportunities and expanded service gross margins; and Cytek's business and operational strategy. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. All statements other than statements of historical facts contained in this presentation, including, without limitation, statements The words “may,” “will," "expect," "anticipate,” “aim,” “estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to the inability to timely complete or complete at all the transaction because of the failure to satisfy conditions to closing; the risk that the transaction disrupts Cytek's current plans and operations or diverts management's attention from its ongoing business; Cytek's ability to integrate the operations and employees of the FCI business; Cytek's ability to recognize the anticipated benefits of the transaction; Cytek's ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and retain key employees; uncertainties relating to market conditions; supply chain risks and Cytek's dependence on certain sole and single source suppliers; competition; market acceptance of Cytek's current and potential products; Cytek's ability to maintain, protect and enhance its intellectual property; and Cytek's ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations. Information on these and additional risks and uncertainties and other information affecting Cytek's business and operating results is contained in Cytek's Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Except as required by applicable law, Cytek does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and Cytek's own internal estimates and research. While Cytek believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. While Cytek believes its internal research is reliable, such research has not been verified by any independent source. Cytek's estimates are derived from publicly available information, management's knowledge of the Cytek's industry and management's assumptions based on such information and knowledge, which they believe to be reasonable. This data involves a number of assumptions and limitations which are necessarily subject to a high degree of uncertainty and risk due to a variety of factors. This presentation contains adjusted EBITDA and adjusted gross margin, financial measures that are not in accordance with Generally Accepted Accounting Principles (GAAP). Reconciliations of adjusted EBITDA and adjusted gross margin to the most comparable GAAP measures are included at the end of this slide presentation. We present adjusted EBITDA and adjusted gross margin because we believe they are frequently used by analysts, investors and other interested parties to evaluate companies in our industry and it facilitates comparisons on a consistent basis across reporting periods. Further, we believe it is helpful in highlighting trends in our operating results because it excludes items that are not indicative of our core operating performance. Cytek and Northern Lights are trademarks or registered trademarks of Cytek Biosciences, Inc. Other trademarks appearing in this presentation are the property of their respective holders. CYTEK TRANSCEND THE CONVENTIONAL 2#3Cytek to Acquire Amnis & Guava Lines from Luminex Cytek's Operational and Shareholder Goals Capital Efficiency Operation Excellence CYTEK TRANSCEND THE CONVENTIONAL Maximize Free Cash Flow FOOTNOTE Commitment to Shareholder Value Creation Maintain Positive EBITDA on annual basis Execution Speed Smart Acquisitions, Licenses and Joint Ventures 3#4Strategic Rationale: Cytek to Acquire Amnis & Guava Lines O High synergy to core business Cell Imaging, Al Bioinformatics, and Capillary Fluidics CYTEK TRANSCEND THE CONVENTIONAL Rapid revenue expansion from larger global footprint ull Cytek's Cell Sorting with Amnis imaging technology COT Synergies in go-to-market and service functions. Increase in operating leverage New markets and research areas for Cytek machines. =$ Substantial accretion to Cytek's revenue#5Cytek + Amnis: New and Cross-Platform Creates New Revenue Opportunities for Cytek Amnis Imaging Technology Enables Cytek to offer enhanced spatial analysis: Single Cell Spatial Features ✓ Cell - Cell Interactions CYTEK TRANSCEND THE CONVENTIONAL Aurora Sorter Technology + Amnis Imaging Aurora Sorting + Amnis Provides: Sorting for Downstream Cell Culturing Unique Cell Cultures. Available for Further Analysis Technology Al Bioinformatics Based on Deep Neuronal Networks Artificial Intelligence in Bioinformatics: Image Recognition "Learns" From Experience ✓ Automated "Tagging" of Unique Cell Populations Capillary Micro Fluidics Capillary Flow Cytometry Offers: ✓ Reduced Cost of Goods, Higher Gross Margins ✓ Ease of Use More Features in Cytek Products = New Revenue Opportunities#6Combined Global Commercial Teams Expected to Drive Accelerated Sales for Cytek Cytek Commercial Team of Cytometry Experts Expected to Expand by: 50% in China / APAC >80% in EMEA Would take years to build organically Large and Loyal Amnis and Guava customer base built over years CYTEK TRANSCEND THE CONVENTIONAL + >7,000 >1,500 >70 Units Placed Customers Countries Accelerated Sales Opportunity for Aurora and Northern Lights CYTEK AURORA 6#7Cytek + Amnis & Guava: Operational Benefits from a Larger Global Platform CYTEK TRANSCEND THE CONVENTIONAL Cytek >1,500 Units Placed Amnis and Guava >7,000 Units Placed + Combined larger installed base ✓ Quicker Access by Field Personnel Globally More Effective Service / Support ✓ More Efficient Service / Support Enables Cytek to Expand Service Gross Margins Positions Cytek for Future Clinical Expansion Cytek#8Strengthen High End and extend the core Technology Expansion Amnis and Guava strategic fit and opportunity Main Applications CYTEK TRANSCEND THE CONVENTIONAL Mid Range Entry Level & Personal Flow Image Flow Image Sort Aurora Analyzer & Sorter Northern Lights Guava EasyCyte & Muse Amnis New to be developed ● ● ● ● High-plex Analysis Immuno-Oncology Cell Therapy Research L&L, MRD Lower-plex Analysis Cell biology, apoptosis, cell cycle Cell counting & viability Disease Profiling QC assays Cell morphology, intracellular translocation, cell-cell interaction in immunology, neurobiology, stem cell research Cell sorting for downstream cell culturing and further analysis ● Main Customers & Markets Academic Core Labs, Pharma/Biotech Developed world Individual labs, academia and industry Developed and developing world Core and individual labs in academia and industry Flow Cytometry Market 2023 Greater Market Presence Creates Greater Growth Opportunity ✓ New Product Capabilities Create Market Expansion Opportunity $4.3 B $1.1 B Increased market share Market expansion#9Complementary Global Presence Cytek % Revenue by Industry 58% 42% CYTEK TRANSCEND THE CONVENTIONAL Academic and Government- Owned Institutions Pharmaceutical and Biotechnology Companies, Distributors and CROS Luminex Flow % Revenue by Industry 30% ● 70% Academic and Government- Owned Institutions Pharmaceutical and Biotechnology Companies, Distributors and CROS Fremont, CA: Cytek HQ Cytek % Revenue by Region ¹ USA 59% ΕΜΕΑ 24% USA 49% Luminex Flow % Revenue by Region² APAC 17% EMEA 38% APAC 13% 1. YTD Q3 2022 2. FY 2021 9#10Strategic Rationale: Cytek to Acquire Amnis & Guava Lines O High synergy to core business Cell Imaging, Al Bioinformatics, and Capillary Fluidics CYTEK TRANSCEND THE CONVENTIONAL Rapid revenue expansion from larger global footprint ul Cytek's Cell Sorting with Amnis Imaging Technology COT Synergies in go-to-market and service functions. Increase in operating leverage New markets and research areas for Cytek machines. =$ Substantial accretion to Cytek's revenue 10#11CYTEK TRANSCEND THE CONVENTIONAL Cytek to Expand Flow Cytometry Portfolio with Amnis and Guava Lines from Luminex Thank You! February 13, 2023